Credit Suisse Group Reaffirms “Outperform” Rating for Intercept Pharmaceuticals (ICPT)

Intercept Pharmaceuticals (NASDAQ:ICPT)‘s stock had its “outperform” rating reaffirmed by stock analysts at Credit Suisse Group in a note issued to investors on Tuesday.

ICPT has been the subject of a number of other research reports. Jefferies Financial Group lifted their price target on Intercept Pharmaceuticals to $150.00 and gave the stock a “buy” rating in a report on Monday, January 28th. Raymond James upgraded Intercept Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a $184.00 price target for the company in a report on Monday, February 4th. JMP Securities upgraded Intercept Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $75.00 to $175.00 in a report on Wednesday, January 30th. Zacks Investment Research upgraded Intercept Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, January 16th. Finally, ValuEngine upgraded Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, November 23rd. Four investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $150.74.

NASDAQ:ICPT opened at $120.05 on Tuesday. The company has a debt-to-equity ratio of 3.83, a quick ratio of 5.98 and a current ratio of 5.98. The stock has a market capitalization of $3.48 billion, a P/E ratio of -8.35 and a beta of 1.88. Intercept Pharmaceuticals has a 52-week low of $51.76 and a 52-week high of $133.74.

In other news, major shareholder S.P.A. Genextra sold 750,000 shares of the business’s stock in a transaction that occurred on Thursday, November 29th. The stock was sold at an average price of $105.07, for a total transaction of $78,802,500.00. Following the completion of the sale, the insider now owns 6,095,578 shares in the company, valued at $640,462,380.46. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider David Shapiro sold 474 shares of the business’s stock in a transaction that occurred on Friday, January 4th. The stock was sold at an average price of $97.48, for a total value of $46,205.52. Following the sale, the insider now owns 37,243 shares of the company’s stock, valued at approximately $3,630,447.64. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 812,130 shares of company stock valued at $85,159,685. Corporate insiders own 4.90% of the company’s stock.

Several large investors have recently modified their holdings of ICPT. Intercontinental Wealth Advisors LLC acquired a new stake in shares of Intercept Pharmaceuticals in the fourth quarter valued at approximately $34,000. Advisor Group Inc. raised its position in shares of Intercept Pharmaceuticals by 63.5% in the fourth quarter. Advisor Group Inc. now owns 739 shares of the biopharmaceutical company’s stock valued at $74,000 after buying an additional 287 shares in the last quarter. Strs Ohio acquired a new stake in shares of Intercept Pharmaceuticals in the third quarter valued at approximately $126,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Intercept Pharmaceuticals by 14.8% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,416 shares of the biopharmaceutical company’s stock valued at $143,000 after buying an additional 183 shares in the last quarter. Finally, Chicago Equity Partners LLC acquired a new stake in shares of Intercept Pharmaceuticals in the third quarter valued at approximately $215,000. Institutional investors own 63.48% of the company’s stock.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia.

Featured Story: How Do You Calculate Return on Investment (ROI)?

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply